BeOne Medicines (ONC) Stock Forecast: StockMap's 2-Week Call
ONC stock forecast: StockMap's model leans Outperform on BeOne Medicines for the two weeks after the Nov 19 close, toward ONC doing better than the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 4 of 5 two-week windows on ONC since Sep 10; by chance, a call on the same dates was right 38% of the time.
BeOne Medicines last closed at $399.70, -0.97% on the session.
Against the IVW growth benchmark the position is +1.36% over the forecast window.
BeOne Medicines' market cap is $43.88B as of November 19, 2026.
Leans up ↗: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 21 (too close to call).
Where ONC sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 11 bullish and 4 bearish.
Agreement across those insights is 73%.
24 daily calls for ONC so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks BeOne Medicines in the 8th percentile on valuation and the 70th percentile on return on equity, where 100 is best.
BeOne Medicines is classified under Health Care / Biotechnology.
StockMap tracks BeOne Medicines as the 8th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite BeOne Medicines ranks 17th of 394 in the group, against a group median of -0.27.